GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aoxing Pharmaceutical Co Inc (OTCPK:AOXG) » Definitions » Beneish M-Score

Aoxing Pharmaceutical Co (Aoxing Pharmaceutical Co) Beneish M-Score : 0.00 (As of Jun. 10, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Aoxing Pharmaceutical Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Aoxing Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Aoxing Pharmaceutical Co was 0.00. The lowest was 0.00. And the median was 0.00.


Aoxing Pharmaceutical Co Beneish M-Score Historical Data

The historical data trend for Aoxing Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aoxing Pharmaceutical Co Beneish M-Score Chart

Aoxing Pharmaceutical Co Annual Data
Trend Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.01 -4.21 -2.14 -0.72 -1.54

Aoxing Pharmaceutical Co Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 -1.54 -1.47 -1.46 -2.04

Competitive Comparison of Aoxing Pharmaceutical Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Aoxing Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aoxing Pharmaceutical Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aoxing Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Aoxing Pharmaceutical Co's Beneish M-Score falls into.



Aoxing Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Aoxing Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.7677+0.528 * 1.032+0.404 * 1.1314+0.892 * 0.9588+0.115 * 0.5887
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.7295+4.679 * -0.002513-0.327 * 1.0933
=-1.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar17) TTM:Last Year (Mar16) TTM:
Total Receivables was $15.29 Mil.
Revenue was 5.702 + 8.009 + 7.569 + 8.825 = $30.11 Mil.
Gross Profit was 4.421 + 6.296 + 6.054 + 6.164 = $22.94 Mil.
Total Current Assets was $34.80 Mil.
Total Assets was $62.47 Mil.
Property, Plant and Equipment(Net PPE) was $24.04 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.99 Mil.
Selling, General, & Admin. Expense(SGA) was $18.99 Mil.
Total Current Liabilities was $43.97 Mil.
Long-Term Debt & Capital Lease Obligation was $0.10 Mil.
Net Income was 0.132 + -0.043 + 0.346 + -1.898 = $-1.46 Mil.
Non Operating Income was 0.069 + 0.017 + -0.004 + -0.025 = $0.06 Mil.
Cash Flow from Operations was -3.017 + 0.088 + 0.135 + 1.431 = $-1.36 Mil.
Total Receivables was $9.02 Mil.
Revenue was 6.564 + 8.196 + 8.745 + 7.895 = $31.40 Mil.
Gross Profit was 4.934 + 6.469 + 6.987 + 6.296 = $24.69 Mil.
Total Current Assets was $29.32 Mil.
Total Assets was $58.93 Mil.
Property, Plant and Equipment(Net PPE) was $26.59 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.63 Mil.
Selling, General, & Admin. Expense(SGA) was $11.45 Mil.
Total Current Liabilities was $38.03 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(15.287 / 30.105) / (9.02 / 31.4)
=0.507789 / 0.287261
=1.7677

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(24.686 / 31.4) / (22.935 / 30.105)
=0.786178 / 0.761834
=1.032

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (34.803 + 24.04) / 62.466) / (1 - (29.319 + 26.589) / 58.929)
=0.058 / 0.051265
=1.1314

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=30.105 / 31.4
=0.9588

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.632 / (0.632 + 26.589)) / (0.987 / (0.987 + 24.04))
=0.023217 / 0.039437
=0.5887

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(18.986 / 30.105) / (11.45 / 31.4)
=0.630659 / 0.36465
=1.7295

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.1 + 43.971) / 62.466) / ((0 + 38.028) / 58.929)
=0.70552 / 0.645319
=1.0933

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-1.463 - 0.057 - -1.363) / 62.466
=-0.002513

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Aoxing Pharmaceutical Co has a M-score of -1.96 suggests that the company is unlikely to be a manipulator.


Aoxing Pharmaceutical Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Aoxing Pharmaceutical Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Aoxing Pharmaceutical Co (Aoxing Pharmaceutical Co) Business Description

Traded in Other Exchanges
N/A
Address
624 Tyvola Road, Suite 103, No. 186, Charlotte, NC, USA, 28217
Aoxing Pharmaceutical Co Inc is a specialty pharmaceutical company. The company specializes in research, development, manufacturing, and distribution of a variety of narcotic, pain-management, and addiction treatment pharmaceutical products. Aoxing holds approximately 139 drug production certificates covering narcotic pain-management, exclusive prescription medicines, OTC and API products. It derives all its revenue from the People's Republic of China.
Executives
Wilfred Chow officer: Chief Financial Officer 30 WEST STREET, 3B, NEW YORK NY 10004
John P Oshea director C/O WESTMINSTER SECURITIES CORP, 100 WALL ST, 7TH FLOOR, NEW YORK NY 10005
John Leo director, officer: Secretary 80 WALL STREET, 5TH FLOOR, NEW YORK NY 10005

Aoxing Pharmaceutical Co (Aoxing Pharmaceutical Co) Headlines

No Headlines